ViewReleaseInStandardHtml

ExpreS2ion Biotech Holding AB’s initial public offering oversubscribed

The 22 June 2016 the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) initial public offering (”IPO”) of shares at Nasdaq Stockholm First North (”First North”) ended. The IPO was subscribed for approximately 19.2 MSEK inclusive subscription commitments, corresponding to a subscription rate of approximately 107 percent. Through the IPO ExpreS2ion gets approximately 440 new share owners and approximately 18 MSEK before emission costs. The first day of trading is expected to be the 27 July 2016.

Subscription and allotment

The IPO was subscribed at approximately 19.2 MSEK including subscription commitments, corresponding to a subscription rate of approximately 107 percent. Hence the issued guarantee commitments were not activated. Through the IPO, 3 050 000 shares have been issued. ExpreS2ion has therefore raised approximately 18 MSEK before emission costs of approximately 1.4 MSEK. Settlement notes are planned to be sent out today the 29 June 2016.

CEO Steen Klysner comments

– We are very pleased with the great interest generated by the IPO of ExpreS2ion and that so many have chosen to subscribe shares in the company. We have thereby received the resources we need to expand our marketing efforts and to continue the development the ExpreS2 platform in a manner facilitating the profitability of the company in the long run. With these words I greet all our new shareholders and welcome you to ExpreS2ion!

Listing on First North

The first trading day of ExpreS2ion’s shares at First North is expected to be the 27 July 2016.

Number of shares and share capital

When ExpreS2ion’s IPO is registered at Bolagsverket, the total number of shares will increase to 8 728 739 shares and the share capital to 969 859.89 SEK. There are no outstanding subscription rights at ExpreS2ion.

Financial Advisors and Certified Advisor

Sedermera Fondkommission is the financial advisor for ExpreS2ion in relation to the planned Initial Public Offering and listing on Nasdaq Stockholm First North. Sedermera Fondkommission is also appointed as Certified Adviser for the company.

For further information about the Initial Public Offering, please contact:

Sedermera Fondkommission
Phone: +46 (0) 431 - 47 17 00
E-mail: info@sedermera.se

For further information about ExpreS2ion, please contact:

Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2 platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.